



## **Pharsight Launches Phoenix NLME™, Continues to Build Next-Generation Platform for Model-Based Drug Development**

### **Phoenix NLME 1.0 lowers barriers to use of population-based analyses**

**ST. LOUIS, MO – November 2, 2009** – Pharsight, a market-leading provider of software and scientific services to improve productivity and decision-making in clinical drug development, today announced the launch of Phoenix NLME (Nonlinear Mixed Effects), the next generation of the company's data processing and modelling software for population pharmacokinetic and pharmacodynamic (PK/PD) analysis. Phoenix NLME 1.0 replaces Pharsight's WinNonMix® and joins Phoenix™ WinNonlin® and Phoenix Connect™ on the Phoenix™ platform, Pharsight's new desktop software environment that is designed to advance model-based drug development by providing an integrated environment for data analysis, modeling and simulation.

Major features of Phoenix NLME 1.0 include flexible tools to create models from an extensive built-in library of models, graphically, or via user-supplied code. For models built graphically, Phoenix NLME automatically writes the corresponding equations. Code-based models can be submitted through the program's user interface or via batch mode. Phoenix NLME also provides support for model bootstrapping, posterior predictive checks and tools for comparison of model estimation runs.

Other notable features of Phoenix NLME include graphical workflows that integrate data preparation, model selection and generation of tables and figures, and parallelized model estimation engines designed to take advantage of significant speed gains available on modern computers running multiple processors. Phoenix NLME 1.0 can be optionally configured to connect with a drug development organization's computer grids and clusters.

"Phoenix NLME shortens the learning curve for drug development scientists to make initial use of population modelling methods, and also provides high-end functionality required by more advanced modellers," said Daniel Weiner, Ph.D., senior vice president and chief technology officer of Pharsight. "Phoenix NLME offers a powerful combination of population PK/PD analysis tools, estimation engines and model comparison features all available from within the unified Phoenix software environment that provides users with high-quality graphics,

workflow management and interoperability with third-party modelling and simulation tools.”

Concurrent with the release of Phoenix NLME 1.0, Pharsight has released updated versions of Phoenix WinNonlin (version 6.1) and Phoenix Connect (version 1.1) software, both of which were launched in June 2009. Phoenix WinNonlin is the next generation of Pharsight’s industry standard software for PK/PD modeling and noncompartmental analysis. Phoenix Connect integrates applications built on the Phoenix platform with commonly used third-party analysis and modeling tools such as NONMEM®, R®, SAS® and S-PLUS®. Phoenix Connect provides a powerful environment for running NONMEM, with management tools for NONMEM file creation, automatic post-processing of NONMEM output and a comparison module to assist in comparing results of multiple NONMEM models.

Phoenix NLME is optionally compatible with Phoenix WinNonlin, Phoenix Connect and Pharsight Knowledgebase Server™ (PKS™), the company’s enterprise data management system for secure storage and tracking of PK/PD data and analyses.

“The release of Phoenix NLME represents another important milestone in Pharsight’s vision for software to enable model-based drug development and its utility in translational science,” added Dr. Weiner. “The Phoenix platform has been developed to provide a collaborative environment for drug development scientists and to shorten the learning curve to more complex and impactful modelling, which ultimately supports more confident and efficient clinical development decisions. We look forward to introducing the benefits of Phoenix NLME to our Phoenix WinNonlin and WinNonMix user bases and to other population modelling experts in the field.”

### **About Phoenix NLME™**

Phoenix NLME 1.0 is Pharsight’s powerful new data processing and modelling software for population pharmacokinetic and pharmacodynamic (PK/PD) analysis. With a visual workflow engine, high quality graphics, and an easy to use graphical user interface, population PK/PD modeling has never been this accessible, flexible, and powerful. Phoenix NLME lowers the barriers to use of population-based modelling, while providing cutting edge tools that advance the science of drug development. More information about Phoenix NLME is available at [www.pharsight.com](http://www.pharsight.com).

### **About Pharsight**

Pharsight, a Certara™ company, is a market-leading provider of software products and scientific consulting services to help pharmaceutical and biotechnology companies improve their drug development process, regulatory compliance and strategic decision-making. Established in 1995, the company’s

goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products. Pharsight leverages expertise in its software tools and in the disciplines of pharmacology, drug and disease modeling, human genetics, biostatistics, strategic decision-making and regulatory strategy. Headquartered in St. Louis, Missouri, with more than 1200 customers worldwide, Pharsight products and services are used by all of the world's top 50 pharmaceutical firms.

## **About Certara**

Certara is dedicated to improving human health through a broad spectrum of products and services, from molecular discovery to clinical research. Formed in 2008, Certara unites Tripos ([www.tripos.com](http://www.tripos.com)) and Pharsight Corporation ([www.pharsight.com](http://www.pharsight.com)). Tripos provides innovative scientific solutions enabling life science researchers to improve the efficiency of molecular discovery. Pharsight provides software and scientific services to improve productivity and decision-making in clinical drug development. Certara focuses on reducing the barriers between the phases of research to speed discoveries in chemistry and enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products.

## **Registered Trademarks and Trademarks**

Pharsight, Phoenix, Phoenix NLME, Phoenix WinNonlin, Phoenix Connect, Pharsight Knowledgebase Server, PKS, WinNonlin, WinNonMix and Certara are trademarks or registered trademarks of Tripos, L.P. All other brands and product names are trademarks or registered trademarks of their respective holders.

### **Pharsight Contact:**

Adam Rutkin, 650-314-3752

Director of Marketing

[arutkin@pharsight.com](mailto:arutkin@pharsight.com)

##